Co-treatment with a novel heat shock protein (hsp) 90 inhibitor IPI504 and the histone deacetylase inhibitor (HDI) vorinostat (suberoylanilide hydroxamic acid, SAHA): A highly active combination against wild type or mutant Bcr-Abl-T315I or FLT-3-ITD-containing human leukemia cells.

被引：0
|
作者：
Fiskus, W
Bali, P
Pranpat, M
Balasis, M
Kumaraswamy, S
Boyapalle, S
Rocha, K
Tong, J
Richon, V
Normant, E
Bhalla, K
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[2] Infin Pharmaceut Inc, Cambridge, MA USA
[3] Merck & Co Inc, Boston, MA USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
10.1182/blood.V106.11.4461.4461
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4461
引用
收藏
页码：193B / 194B
页数：2
相关论文
共 2 条
  • [1] Co-treatment with the novel, oral, multi-targeted kinase inhibitor, dasatinib (BMS-354825) and the histone deacetylase inhibitor corinostat (suberoylanilide hydroxamic acid, SAHA): A highly active combination against wild-type or mutant Bcr-Abl-T315I containing human leukemia cells.
    Fiskus, W
    Pranpat, M
    Bali, P
    Balasis, M
    Kumaraswamy, S
    Boyapalle, S
    Rocha, K
    Lee, F
    Richon, V
    Bhalla, K
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9028S - 9028S
  • [2] Co-treatment with the hsp90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and histone deacetylase inhibitor (HDI) vorinostat (suberoylanilide hydroxamic acid, SAHA): A highly active combination against human mantle cell lymphoma (MCL) cells.
    Hatter, A
    Bali, P
    Balasis, M
    Fiskus, W
    Boyapalle, S
    Kumaraswamy, S
    Rocha, K
    Pranpat, M
    Hannah, A
    Sotomayor, E
    Richon, V
    Bhalla, K
    BLOOD, 2005, 106 (11) : 680A - 680A
1